Acquisition of Services for cGMP Testing of PEN-866 Drug Conjugate
ID: 75N91025Q00045Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNIH NCIBethesda, MD, 20892, USA

NAICS

Testing Laboratories and Services (541380)

PSC

MEDICAL- LABORATORY TESTING (Q301)

Original Source

https://sam.gov/opp/904eaefa46034469973d59145fca9884/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure services for the generation of a new Certificate of Analysis (CoA) for the drug conjugate PEN-866, which is critical for ongoing clinical trials involving pediatric and young adult cancer patients. The selected contractor will be responsible for conducting comprehensive testing and analysis under strict Current Good Manufacturing Practice (cGMP) regulations, ensuring the drug's stability and compliance throughout the trial period. PEN-866 is an important HSP90 inhibitor-drug-conjugate that has shown promise in tumor regression and survival improvement in various pediatric sarcoma models. Interested parties must submit their capability statements or proposals to Contracting Officer John Russell at John.Russell3@nih.gov by 10:00 A.M. EST on July 18, 2025, referencing notice number 75N91025Q00045. This acquisition will be processed as a sole source contract with PPD Development LP, the only vendor with established testing protocols for PEN-866.

    Point(s) of Contact
    John Russell, Contracting Officer
    John.Russell3@nih.gov
    Files
    Title
    Posted
    NCI_SOW_PEN-866_Testing.pdf
    The National Institutes of Health's Pediatric Oncology Branch seeks to acquire services for generating a new Certificate of Analysis (CoA) for the drug conjugate PEN-866, which targets tumor protein HSP90 for cancer treatment. Due to delays from the pandemic affecting the previous CoA, a new one is required for clinical trials involving pediatric and young adult patients. The contractor will carry out tasks under strict Current Good Manufacturing Practice (cGMP) regulations including method verification, drug analysis with comprehensive testing parameters, and long-term storage. The work is segmented into specific tasks such as familiarization with established methods, conducting detailed analyses on the drug's compliance, and preparing the CoA, all within specified timeframes. Additionally, options for ongoing testing and storage are outlined for up to four years post-initial certification. All deliverables must meet accessibility standards, ensuring compliance and equal access to information. Overall, the file outlines the framework for safe testing and analysis of PEN-866, essential for its further development in treating cancer in young patients.
    Lifecycle
    Title
    Type
    Acquisition of Services for cGMP Testing of PEN-866 Drug Conjugate
    Currently viewing
    Presolicitation
    Similar Opportunities
    NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022D00017 WITH THE EMMES COMPANY, LLC.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source modification under Contract No. 75N95022D00017 to The Emmes Company, LLC, increasing the contract value by $13,158,436 to a total of $44,313,082. This modification aims to ensure the continuation of critical support services for ongoing and upcoming clinical trials related to substance use disorders, particularly in response to the national opioid crisis. The contract encompasses a range of services, including the establishment of secure data management systems, clinical trial design and analysis, and quality monitoring of study data. Interested parties may submit capability statements or objections to the proposed modification by December 30, 2025, to the primary contact, Llakim Dubroff, at llakim.dubroff@nih.gov.
    Notice of Intent to Sole Source 2 sets of QX200 ddPCR Systems
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the Clinical Center (CC), intends to negotiate a sole-source contract for the renewal of maintenance services for two QX200 AutoDG ddPCR Systems from Bio-Rad Laboratories. This five-year service contract, valued at $151,494, is essential for the ongoing maintenance and support of these systems, which are critical for droplet digital PCR (ddPCR) vector copy number detection and gene modification efficiency testing on clinical cellular products. The contract ensures compliance with FDA regulations and is vital for patient care testing, as failure to secure these services could adversely affect patient safety. Interested parties may submit capability statements by December 18, 2025, to valerie.gregorio@nih.gov, referencing NOI-CC-26-000112.
    Single-Nuclei Multiome Analysis of Human Brain Tissue, iPSC-Derived Cells and Human Dorsal Root Ganglion
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified entities to conduct a Single-Nuclei Multiome Analysis of Human Brain Tissue, iPSC-Derived Cells, and Human Dorsal Root Ganglion. This procurement aims to advance research in medical laboratory testing by analyzing complex biological samples to enhance understanding of neurological conditions. The work is critical for developing innovative treatments and therapies in the field of neuroscience. Interested parties can reach out to Maggie Brant at maggie.brant@nih.gov or KJ Shaikh at KJ.Shaikh@nih.gov for further details regarding this opportunity.
    PREVENT Cancer Preclinical Drug Development Program
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to increase the programmatic ceiling for several contracts under the PREVENT Cancer Preclinical Drug Development Program. This initiative aims to enhance funding for ongoing contracts numbered 75N91019D00012 through 75N91019D00026, which are focused on health research and development services critical to advancing cancer treatment options. The adjustments to the contract values are essential for supporting continued research efforts in the field of cancer prevention and treatment. For further inquiries, interested parties can contact Rachel Turk at rachel.turk@nih.gov.
    A--Study Coordinating Center for Lung Health Cohort
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking small businesses to participate in a Sources Sought notice for the establishment of a Study Coordinating Center for the Lung Health Cohort. The objective of this procurement is to identify qualified entities that can provide research and development services in the health sector, particularly focusing on lung health. This initiative is crucial for advancing understanding and treatment of lung-related health issues, which have significant implications for public health. Interested parties can reach out to Lynn M. Furtaw at lynn.furtaw@nih.gov or call +1 301 435 0330 for further information regarding this opportunity.
    Notice of Intent to Sole Source – Werfen USA, LLC
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), intends to award a sole source contract to Werfen USA, LLC for the procurement of kits and reagents essential for patient care testing, specifically for use with the ACL TOP 350 and 750 analyzers. This procurement, valued at approximately $570,000 over a base year and two option years (January 1, 2026, to December 31, 2028), is critical as the reagents are uniquely validated for the existing instruments, ensuring continuity in patient care and research protocols. The acquisition will be conducted under the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, allowing for increased procedural flexibility and efficiency. Interested parties may submit comments regarding this notice to Ryssa Nix at ryssa.nix@nih.gov by the close date of December 23, 2025, at 12 PM EST.
    Notice of Intent to Sole Source – Stemcell Technologies
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to StemCell Technologies Inc. for the procurement of EasySep cell separator kits for the Department of Laboratory Medicine at the NIH Clinical Center. These kits are essential for use with RoboSep instruments currently utilized in the laboratory, and StemCell Technologies is the sole manufacturer capable of meeting the specific clinical and research requirements of the department. Interested parties may express their interest and capabilities regarding this procurement, but the government retains discretion over the decision not to compete the requirement. Comments and inquiries should be directed to Kristin Nagashima at kristin.nagashima@nih.gov by December 19, 2025, at 12 PM EST.
    Support for Evaluating and Conducting Computational and Alternative Toxicological Methods for the National Institute of Environmental Health Sciences
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institute of Environmental Health Sciences (NIEHS), is seeking proposals from small businesses to support the evaluation and conduct of computational and alternative toxicological methods. The objective of this procurement is to assist NIEHS in chemical hazard and risk assessment while minimizing the use of animal testing, focusing on areas such as population variability, developmental neurotoxicity, and carcinogenicity. This contract, which is a Cost-Plus-Fixed-Fee type, has a base period of performance from June 1, 2026, to May 31, 2027, with nine additional one-year options and a potential six-month extension. Proposals are due by December 19, 2025, and must be submitted electronically via the NIH eCPS website; interested parties can contact Jason Williams at jason.williams2@nih.gov or Lisa Schaupp at lisa.schaupp@nih.gov for further information.
    Preventative Maintenance Agreement for 36 Heracell Vios 160i CO2 incubators
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), intends to award a firm-fixed-price contract to Thermo Fisher Scientific for a preventative maintenance agreement covering 36 HERA VIOS 160i CO2 incubators. This sole-source acquisition is essential for maintaining critical equipment used in the manufacturing of cell-based therapies, as mandated by the FDA's regulations on controlled maintenance of such equipment. The estimated cost for this project is $55,311.32, and it is crucial for ensuring the continuous, compliant operation of equipment vital for patient care. Interested parties may submit capability statements by email to valerie.gregorio@nih.gov by 11:00 AM EST on December 18, 2025, referencing the notice of intent (NOI-CC-26-000054).
    GraphPad Prism Subscription Renewal
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to renew a contract for 500 subscriptions of GraphPad Prism software, which is critical for biostatistical analysis and scientific graphing. This non-competitive procurement is justified under the Federal Acquisition Regulation (FAR) due to GraphPad Software, LLC being the sole provider of the software, with the renewal period set from April 8, 2025, to April 7, 2026. GraphPad Prism is widely utilized by research institutions and pharmaceutical companies, ensuring the accuracy and efficiency of scientific data analysis within the NIH. Interested vendors may express their capabilities, but the government retains discretion over competitive offers, with the total contract value not exceeding $250,000. For inquiries, contact Verne L. Griffin at verne.griffin@nih.gov or 301-594-7730, or Michael L. Falzone at michael.falzone@nih.gov or 301-827-1873.